TY - JOUR
T1 - Testosterone treatment and sexual function in older men with low testosterone levels
AU - Cunningham, Glenn R.
AU - Stephens-Shields, Alisa J.
AU - Rosen, Raymond C.
AU - Wang, Christina
AU - Bhasin, Shalender
AU - Matsumoto, Alvin M.
AU - Parsons, J. Kellogg
AU - Gill, Thomas M.
AU - Molitch, Mark E.
AU - Farrar, John T.
AU - Cella, David
AU - Barrett-Connor, Elizabeth
AU - Cauley, Jane A.
AU - Cifelli, Denise
AU - Crandall, Jill P.
AU - Ensrud, Kristine E.
AU - Gallagher, Laura
AU - Zeldow, Bret
AU - Lewis, Cora E.
AU - Pahor, Marco
AU - Swerdloff, Ronald S.
AU - Hou, Xiaoling
AU - Anton, Stephen
AU - Basaria, Shehzad
AU - Diem, Susan J.
AU - Tabatabaie, Vafa
AU - Ellenberg, Susan S.
AU - Snyder, Peter J.
N1 - Funding Information:
The Testosterone Trials were supported by a grant from the National Institute on Aging (NIA), National Institutes of Health (NIH) (U01 AG030644), supplemented by funds from the National Heart, Lung, and Blood Institute, National Institute of Neurological Diseases and Stroke, and National Institute of Child Health and Human Development. AbbVie (formerly Solvay and Abbott Laboratories) generously provided funding, AndroGel and placebo gel. C.W. reports funding from CTSI (UL1TR000124). The Boston site was supported partly by the Boston Claude D. Pepper Older Americans Independence Center. A.M.M. was supported by the Department of Veterans Affairs Puget Sound Health Care System. T.M.G. is the recipient of an Academic Leadership Award (K24-AG021507) from the NIA. The Yale Field Center was partially supported by the Claude D. Pepper Older Americans Independence Center (P30-AG021342) and Yale CTSA (UL1 TR000142). C.E.L. was supported by the National Institute of Diabetes and Digestive and Kidney Diseases, NIH
PY - 2016/8
Y1 - 2016/8
N2 - Context: The Testosterone Trials are a coordinated set of seven trials to determine the efficacy of T in symptomatic men ≥65 years old with unequivocally low T levels. Initial results of the Sexual Function Trial showed that T improved sexual activity, sexual desire, and erectile function. Objective: To assess the responsiveness of specific sexual activities to T treatment; to relate hormone changes to changes in sexual function; and to determine predictive baseline characteristics and T threshold for sexual outcomes. Design: A placebo-controlled trial. Setting: Twelve academic medical centers in the United States. Participants: A total of 470 men ≥65 years of age with low libido, average T <275 ng/dL, and a partner willing to have sexual intercourse at least twice a month. Methods: Men were assigned to take T gel or placebo for 1 year. Sexual function was assessed by three questionnaires every 3 months: the Psychosexual Daily Questionnaire, the Derogatis Interview for Sexual Function, and the International Index of Erectile Function. Results: Compared with placebo, T administration significantly improved 10 of 12 measures of sexual activity. Incremental increases in total and free T and estradiol levels were associated with improvements in sexual activityanddesire, but not erectile function.Nothreshold T levelwasobserved for any outcome, and none of the 27 baseline characteristics predicted responsiveness to T. Conclusions: In older men with low libido and low T levels, improvements in sexual desire and activity in response to T treatment were related to the magnitude of increases in T and estradiol levels, but there was no clear evidence of a threshold effect.
AB - Context: The Testosterone Trials are a coordinated set of seven trials to determine the efficacy of T in symptomatic men ≥65 years old with unequivocally low T levels. Initial results of the Sexual Function Trial showed that T improved sexual activity, sexual desire, and erectile function. Objective: To assess the responsiveness of specific sexual activities to T treatment; to relate hormone changes to changes in sexual function; and to determine predictive baseline characteristics and T threshold for sexual outcomes. Design: A placebo-controlled trial. Setting: Twelve academic medical centers in the United States. Participants: A total of 470 men ≥65 years of age with low libido, average T <275 ng/dL, and a partner willing to have sexual intercourse at least twice a month. Methods: Men were assigned to take T gel or placebo for 1 year. Sexual function was assessed by three questionnaires every 3 months: the Psychosexual Daily Questionnaire, the Derogatis Interview for Sexual Function, and the International Index of Erectile Function. Results: Compared with placebo, T administration significantly improved 10 of 12 measures of sexual activity. Incremental increases in total and free T and estradiol levels were associated with improvements in sexual activityanddesire, but not erectile function.Nothreshold T levelwasobserved for any outcome, and none of the 27 baseline characteristics predicted responsiveness to T. Conclusions: In older men with low libido and low T levels, improvements in sexual desire and activity in response to T treatment were related to the magnitude of increases in T and estradiol levels, but there was no clear evidence of a threshold effect.
UR - http://www.scopus.com/inward/record.url?scp=84984700625&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84984700625&partnerID=8YFLogxK
U2 - 10.1210/jc.2016-1645
DO - 10.1210/jc.2016-1645
M3 - Article
C2 - 27355400
AN - SCOPUS:84984700625
SN - 0021-972X
VL - 101
SP - 3096
EP - 3104
JO - Journal of Clinical Endocrinology and Metabolism
JF - Journal of Clinical Endocrinology and Metabolism
IS - 8
ER -
